<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:mp ids='MP_0004027'>Trisomy</z:mp> for chromosome 7 is frequently observed as an initiating event in <z:hpo ids='HP_0003745'>sporadic</z:hpo> <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Although unstable chromosome numbers and recurrent <z:mp ids='MP_0004024'>aneuploidies</z:mp> drive a large fraction of human <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e>, targeted therapies selective to pre-neoplastic trisomic cells are non-existent </plain></SENT>
<SENT sid="2" pm="."><plain>We have previously characterized a <z:mp ids='MP_0004027'>trisomy</z:mp> 7 cell line (1CT+7) spontaneously derived from <z:mpath ids='MPATH_458'>normal</z:mpath> diploid human colonic epithelial cells that aberrantly expresses the epidermal growth factor receptor (EGFR, chromosome 7p11) </plain></SENT>
<SENT sid="3" pm="."><plain>Recent studies identified AICAR (5-<z:chebi fb="0" ids="22512">aminoimidazole</z:chebi>-4-<z:chebi fb="0" ids="23004,37622">carboxamide</z:chebi>-1-Î²-D-ribofuranoside) as a pharmacological inhibitor of aneuploid murine <z:mpath ids='MPATH_180'>fibroblast proliferation</z:mpath> </plain></SENT>
<SENT sid="4" pm="."><plain>Here, we report that AICAR induces profound <z:chebi fb="0" ids="35610">cytostatic</z:chebi> and metabolic effects on 1CT+7 cells, but not on their isogenic diploid counterpart </plain></SENT>
<SENT sid="5" pm="."><plain>Dose-response experiments indicate that 1CT+7 cells are fourfold preferentially sensitive to AICAR compared to diploid cells </plain></SENT>
<SENT sid="6" pm="."><plain>Unexpectedly, treatment of 1CT+7 cells with AICAR led to a reversible 3.5-fold reduction (P=0.0025) in EGFR overexpression </plain></SENT>
<SENT sid="7" pm="."><plain>AICAR-induced <z:mpath ids='MPATH_63'>depletion</z:mpath> of EGFR protein can be abrogated through inhibition of the proteasome with MG132 </plain></SENT>
<SENT sid="8" pm="."><plain>AICAR also heavily promoted EGFR ubiquitination in cell-based immunoprecipitation assays, suggesting enhanced degradation of EGFR protein mediated by the proteasome </plain></SENT>
<SENT sid="9" pm="."><plain>Moreover, treatment with AICAR reduced EGFR protein levels in a panel of human <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> cells in vitro and in xenograft <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> in vivo </plain></SENT>
<SENT sid="10" pm="."><plain>Our data collectively support the pharmacological compound AICAR as a novel inhibitor of EGFR protein abundance and as a potential anticancer agent for <z:mp ids='MP_0004024'>aneuploidy</z:mp>-driven <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>.Oncogene advance online publication, 13 August 2012; doi:10.1038/onc.2012.339 </plain></SENT>
</text></document>